Although not yet approved for clinical use, CYT107, a glycosylated recombinant human IL-7 (rhIL-7), has been evaluated in clinical trials involving adult and pediatric patients for a range of disorders, including HIV, idiopathic lymphopenia, cancer, hepatitis C, and bone marrow reconstitution following stem cell transplantation. Here, IL7 is linked to lymphopenia.